Tumor necrosis factor-alpha (TNF-α) inhibitors, such as infliximab, adalimumab, and etanercept, have been used as steroid-sparing agents in the management of VEXAS syndrome, though their efficacy appears to be limited. This evidence concerns the gene TNF and VEXAS syndrome.